4.3 Review

Postinfection Irritable Bowel Syndrome

期刊

GUT AND LIVER
卷 16, 期 3, 页码 331-340

出版社

EDITORIAL OFFICE GUT & LIVER
DOI: 10.5009/gnl210208

关键词

Gastrointestinal disorders; Enteritis; Dysentery; COVID-19; Tropical sprue

向作者/读者索取更多资源

Postinfection IBS (PI-IBS) is a subset of patients developing new onset IBS following acute gastroenteritis, with a prevalence rate of 11.5%. Various factors are associated with the development of PI-IBS, suggesting a potential organic basis. More studies are needed to explore the treatment of PI-IBS, as randomized controlled trials are rare.
Following acute gastroenteritis (AGE) due to bacteria, viruses, or protozoa, a subset of patients develop new onset Rome criteria positive irritable bowel syndrome (IBS), called postinfection IBS (PI-IBS). The pooled prevalence of PI-IBS following AGE was 11.5%. PI-IBS is the best natural model that suggests that a subset of patients with IBS may have an organic basis. Several factors are associated with a greater risk of development of PI-IBS following AGE including female sex, younger age, smoking, severity of AGE, abdominal pain, bleeding per rectum, treatment with antibiotics, anxiety, depression, somatization, neuroticism, recent adverse life events, hypochondriasis, extroversion, negative illness beliefs, history of stress, sleep disturbance, and family history of functional gastrointestinal disorders (FGIDs), currently called disorder of gut-brain interaction. Most patients with PI-IBS present with either diarrhea-predominant IBS or the mixed subtype of IBS, and overlap with other FGIDs, such as functional dyspepsia is common. The drugs used to treat non-constipation IBS may also be useful in PI-IBS treatment. Since randomized controlled trials on the efficacy of drugs to treat PI-IBS are rare, more studies are needed on this issue. (Gut Liver 2022;16:331-340)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据